What is the Science Translational Medicine JIF?

The JIF is 15.6. See the full year-by-year trend and category ranking in our Science Translational Medicine JIF analysis.

What is the acceptance rate of Science Translational Medicine?

Manusights currently treats Not publicly disclosed as an estimate for Science Translational Medicine, not an official journal-published rate. One common reason papers fail is submitting basic science dressed up as translational research.

How long does Science Translational Medicine take to review?

Science Translational Medicine typically takes Not publicly disclosed, but timing varies by editor, field, and reviewer availability. Expect an editorial screen first, then presubmission inquiry (strongly recommended), then peer review.

All Journal Guides

Journal Guide

Publishing in Science Translational Medicine: Fit, Timeline & Submission Guide

Q: Is Science Translational Medicine a good journal?

Science Translational Medicine is a strong target if don't tell editors your work 'may have therapeutic implications.' Show them. It is a weaker fit if this is the most common reason for desk rejection.

Q: Is Science Translational Medicine peer reviewed?

Yes, Science Translational Medicine is fully peer reviewed. All submissions undergo rigorous peer review by Manuscripts sent for review can face both mechanistic and translational questions. Treat reviewer count and turnaround as case-specific unless the current AAAS record states otherwise..

Q: What does Science Translational Medicine look for in submissions?

Tangible clinical relevance, not hand-waving: Don't tell editors your work 'may have therapeutic implications.' Show them. If you've identified a target, you'd better have tested an inhibitor. If you've found a biomarker, you'd better have validated it in patient samples. The translational bridge can't just be theoretical - you need to have started building it. Papers that end with 'future clinical studies are warranted' without any preliminary human data usually don't make the cut.

Science Translational Medicine is strongest for research that credibly bridges mechanistic science and human medicine rather than stopping at promising preclinical results.

Should you submit here?

Submit if don't tell editors your work 'may have therapeutic implications.' Show them. Be careful if this is the most common reason for desk rejection.

IF 15.6 · Not publicly disclosed accepted · Not publicly disclosedLast reviewed Jul 10, 20260 official · 0 estimated · 2 unverified signals

Best fit if

Don't tell editors your work 'may have therapeutic implications.' Show them

Not ideal if

This is the most common reason for desk rejection

Also compare

Natureand Cell

15.6

Impact Factor

Not publicly disclosed

Acceptance Rate

Not publicly disclosed

Time to First Decision

Readiness Scan

See whether your manuscript clears Science Translational Medicine’s editorial screen.

Free 1 to 2 minute scan. Get a fit score, top issues, and the specific Science Translational Medicine desk-reject patterns flagged before you submit.

Check my Science Translational Medicine readiness See a sample report

Anthropic Privacy Partner. Your manuscript is never used to train any model.

What Science Translational Medicine Publishes

Science Translational Medicine publishes research at the intersection of science, engineering, and medicine. The strongest fit is work where the translational bridge is already credible: the mechanism, human relevance, and therapeutic, diagnostic, or preventive path reinforce the same contribution. Pure mechanism without a realistic path to application can be too early, while routine clinical work without explanatory depth can be too far downstream.

Preclinical studies with clear, validated biomarkers that can be measured in human patients - not just mouse survival curves.
Early-phase clinical trials that demonstrate proof-of-concept for new therapeutic approaches or reveal unexpected biology in humans.
Diagnostic and prognostic tools that've been tested in real patient samples, not just cell lines or archived specimens.
Drug repurposing studies that show a known compound works through a newly understood mechanism with direct clinical implications.
Disease mechanism papers are acceptable but only if they identify a druggable target and show preliminary evidence that targeting it works.

Editor Insight

“Science Translational Medicine works best when the manuscript already shows a believable path from mechanism to medicine. The page reads better when it is honest about that middle-ground role: not just basic science with a translational paragraph added at the end, and not just clinical observation without mechanistic weight. If the human relevance is concrete and the science still teaches readers something real, the fit improves sharply.”

What Science Translational Medicine Editors Look For

Tangible clinical relevance, not hand-waving

Don't tell editors your work 'may have therapeutic implications.' Show them. If you've identified a target, you'd better have tested an inhibitor. If you've found a biomarker, you'd better have validated it in patient samples. The translational bridge can't just be theoretical - you need to have started building it. Papers that end with 'future clinical studies are warranted' without any preliminary human data usually don't make the cut.

Mechanistic depth backing up clinical observations

Clinical observations alone won't get you in. If you've run a trial and seen an effect, you need to explain why. What's the molecular mechanism? What's the cellular biology? STM readers are scientists first, and they want to understand how things work, not just that they work. This is what distinguishes the journal from purely clinical outlets. The mechanism needs to be novel and important, not a confirmation of what everyone already suspected.

Multiple model systems and human validation

A finding in one mouse strain won't cut it. Editors want to see consistency across multiple animal models, or better yet, across species. And there needs to be human data - patient samples, clinical correlations, or early trial results that show your findings translate. The whole point of the journal is translation, so you can't stop at the mouse. Human relevance can't be assumed; it must be demonstrated.

Quantitative rigor that can inform clinical decisions

Vague claims about 'significant improvement' don't help anyone design a clinical trial. What's the effect size? What's the therapeutic window? How does efficacy compare to existing treatments? Editors want numbers they can use to calculate sample sizes and predict clinical outcomes. If your preclinical data can't inform a realistic clinical development plan, the paper lacks the quantitative foundation the journal requires.

Novelty that matters for patients

Academic novelty isn't the same as clinical novelty. You might have discovered something no one's ever seen before, but if it doesn't change how we'd diagnose or treat disease, STM isn't interested. Conversely, confirming a therapeutic mechanism with human data might not be academically novel, but it could be exactly what the field needs to move forward. The novelty question is always: does this get us closer to helping patients?

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Science Translational Medicine's editorial review:

Submitting basic science dressed up as translational research

This is the most common reason for desk rejection. Researchers add a paragraph about 'clinical implications' to their Discussion and think that's enough. It isn't. Editors can spot this immediately because the experiments stop where basic science papers typically stop - at the mechanism. There's no biomarker development, no therapeutic testing, no human data. If you haven't actually done translational experiments, don't try to frame it as translational research.

Overrelying on a single animal model without human validation

Mouse models fail in human trials constantly. Editors know this, and they're skeptical of papers that show beautiful results in mice without any human correlation. Even preliminary human data - gene expression from patient samples, correlation with clinical outcomes in existing datasets - dramatically strengthens a paper. Without it, reviewers will ask whether your finding is a mouse artifact or a genuine biological principle.

Burying the translational significance in the Discussion

Your Abstract and Introduction need to make the clinical relevance obvious. If editors have to read to page 15 to understand why this matters for patients, they'll assume it doesn't. Many submissions get desk-rejected because the authors couldn't articulate the translational thesis clearly upfront. Lead with the clinical problem, then explain how your work solves it.

Presenting incremental improvements as breakthroughs

Making an existing treatment 20% better in mice doesn't clear the bar unless you've also shown it works in patients. For preclinical work, the improvement needs to be dramatic enough that it's worth the risk and cost of clinical development. STM isn't interested in marginal gains that would never justify a new clinical trial. The translational path has to make economic and practical sense, not just statistical sense.

Ignoring the existing clinical field

Reviewers will immediately ask: how does this compare to current standard of care? If your new therapeutic approach isn't clearly better than what doctors already use, why would anyone develop it? Papers that ignore existing treatments or fail to benchmark against them suggest the authors don't understand the clinical context. You've got to know what's already being done and explain why your approach is superior.

Does your manuscript avoid these patterns?

The Free Readiness Scan reads your full manuscript against Science Translational Medicine's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Science Translational Medicine Authors

Structure your paper around the translational thesis, not the experimental timeline

Most researchers write papers in the order they did experiments. That's backwards for STM. Start with the clinical problem, then show each piece of evidence building toward the solution. The narrative should feel like you're making a case for why this should move into clinical development. Editors respond to papers that read like translational roadmaps.

Include a 'Translational Outlook' or perspective on clinical development

The best STM papers don't just present data - they tell you what should happen next. What clinical trial design makes sense? What patient population should be targeted first? What regulatory hurdles need to be addressed? This demonstrates you've thought beyond the bench and understand what it takes to actually translate findings into practice.

Collaborative author lists signal genuine translation

Papers with both basic scientists and clinicians as authors are viewed more favorably because they suggest real collaboration. If your author list is entirely postdocs from one lab, it raises questions about whether you've engaged with the clinical community. Involving clinicians, even as consultants, strengthens both the science and the perception of translational relevance.

Negative results in human validation can still be publishable

If you show that a promising preclinical finding doesn't hold up in patients, that's valuable information. It saves the field from wasted effort. STM publishes cautionary tales alongside success stories because failed translation is just as informative as successful translation. Don't hide human data that contradicts your mouse results.

Use the Focus article format for disease mechanism papers

If your work is more mechanistic than therapeutic, the Focus format might be more appropriate than a Research Article. Focus pieces allow for more speculation about clinical implications without requiring you to have already done all the translational experiments. It's a good option for early-stage work with strong clinical potential.

The Science Translational Medicine Submission Process

Presubmission inquiry (strongly recommended)

Optional

If fit is uncertain, check the current AAAS author guidance before preparing an inquiry. The useful question is whether the manuscript already shows a believable bridge from mechanism to medicine.

Full manuscript submission

Submission-dependent

Prepare the manuscript against the current AAAS requirements. The main text should make the translational contribution legible without forcing editors to infer it from supplementary material or the cover letter.

Editorial triage

Variable

An editor assesses scope, significance, and whether the translational bridge is credible enough for the journal. Public AAAS pages reviewed here do not support a fixed triage duration or rejection percentage.

Peer review

Variable

Manuscripts sent for review can face both mechanistic and translational questions. Treat reviewer count and turnaround as case-specific unless the current AAAS record states otherwise.

Revision and decision

Revision-dependent

If revision is invited, address the mechanism-to-application boundary directly. The required work and decision timing depend on the reviewer requests and manuscript.

Production and publication

Production-dependent

Accepted papers move through copyediting and proof stages. Use the journal's current production communication for timing rather than a generic estimate.

Science Translational Medicine by the Numbers

2025 Journal Impact Factor(Current value in the 2026 Journal Citation Reports release)	15.6
Acceptance Rate(Current public AAAS pages do not foreground an official acceptance percentage)	Not publicly disclosed
Time to First Decision(Use current author guidance instead of a fixed third-party estimate)	Not publicly disclosed
Open Access Option(Confirm the current license and fee route before submission)	Available

Before you submit

Science Translational Medicine accepts a small fraction of submissions. Make your attempt count.

Start with the Free Readiness Scan. Unlock the Full Review from $39, with local pricing shown before checkout. If you need deeper submission planning, choose the Submission-Ready Dossier. The full report is calibrated to Science Translational Medicine.

Run Free Readiness Scan See a sample report

Article Types

Research Article

Original research in which mechanistic insight and translational relevance support the same contribution. Check current AAAS author instructions for format limits.

Research Resource

Tools, technologies, or datasets intended to enable translational research. Check current AAAS author instructions for eligibility and format limits.

Focus

Commentary or perspective-oriented treatment of a translational topic. Confirm current availability and limits in AAAS author guidance.

Viewpoint

Opinion-oriented discussion of translational science, policy, ethics, or strategy. Confirm current availability and limits in AAAS author guidance.

Editorial

Editorial commentary on developments in translational medicine. Confirm invitation status and format limits with current AAAS guidance.

Landmark Science Translational Medicine Papers

Papers that defined fields and changed science:

Pardoll et al., 2012 - Established the scientific framework for cancer immunotherapy checkpoint blockade that led to multiple FDA approvals
Bhatt et al., 2017 - Demonstrated the microbiome's role in immunotherapy response, changing patient stratification approaches
June et al., 2014 - Published early CAR-T cell therapy results in leukemia patients that preceded FDA approval
Bhattacharya et al., 2021 - Identified transcriptomic signatures predicting COVID-19 severity that informed clinical triage
Bhutani et al., 2019 - Showed CRISPR-based sickle cell therapy feasibility in patient-derived cells, preceding clinical trials

Preparing a Science Translational Medicine Submission?

Get pre-submission feedback from reviewers who've published in Science Translational Medicine and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? See Expert Review Options

NDA-protected

Confidential

Primary Fields

Cancer therapeutics and immunotherapyCardiovascular disease mechanisms and interventionsNeurological and neurodegenerative diseasesInfectious disease and vaccine developmentMetabolic disorders and diabetesGene therapy and genome editing applicationsRegenerative medicine and stem cellsBiomarker discovery and validationDrug delivery and pharmacologyMedical devices and diagnostics

More Guides for This Journal

Ready to submit to Science Translational Medicine?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Science Translational Medicine editors look for.

Need field-expert depth? See Expert Review Options